JAK-STAT Pathway

JAK-STAT Pathway designates a major intracellular signalling mechanism transmitting cytokine and growth factor signals from cell surface receptors to the nucleus, controlling gene expression involved in immunity, inflammation, proliferation, and survival. Activation occurs when cytokine binding triggers JAK phosphorylation, leading to STAT activation and nuclear translocation regulating transcription. This pathway provides rapid communication between extracellular immune signals and cellular response programmes.

The pharmaceutical industry targets the JAK-STAT pathway for treating inflammatory, autoimmune, and haematological disorders. Therapeutic approaches include JAK inhibitors, receptor-blocking antibodies, and cytokine antagonists that reduce downstream STAT activation. Biomarker studies measure STAT phosphorylation and cytokine signatures as pharmacodynamic indicators of target engagement. Safety considerations include immunosuppression-related risks due to broad pathway involvement across multiple cytokines. Research continues exploring selective modulation of specific JAK-STAT combinations to improve therapeutic precision and reduce off-target effects. As pathway biology becomes clearer, JAK-STAT modulation remains central to immunology drug development.